Frankfurt - Delayed Quote EUR

Anavex Life Sciences Corp. (12X1.F)

9.11

-0.08

(-0.87%)

At close: January 31 at 8:16:34 AM GMT+1

Jim Cramer on Anavex Life Sciences Corp. (AVXL): ‘It’s A Good Spec’

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to take a look at where Anavex Life Sciences Corp. (NASDAQ:AVXL) stands against the other stocks. Jim Cramer, the host of Mad Money, recently expressed his concerns about the uncertain economic outlook for 2025, particularly […]

Insider Monkey yesterday

AVXL

^GSPC
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today it was issued a new U.S. Patent No. 12,180,174 entitled “A2-73 CRYSTALLINE POLYMORPH COM

GlobeNewswire 5 days ago

AVXL
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.

Zacks 8 days ago

AVXL
Best Momentum Stocks to Buy for January 21st

CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.

Zacks 11 days ago

CDNA

ALNY

AVXL
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and therefore anticipates the neurodegenerative process in Alzheimer’s disease NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Par

GlobeNewswire 17 days ago

AVXL
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of early treatment initiation Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatm

GlobeNewswire 19 days ago

AVXL
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, J

GlobeNewswire 26 days ago

AVXL
Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?

Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year.

Zacks last month

AVXL

ABBV
All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy

Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks last month

AVXL
Anavex price target raised to $42 from $40 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Anavex (AVXL) to $42 from $40 and keeps a Buy rating on the shares after the company announced the acceptance of the blarcamesine Marketing Authorization Application for the treatment of Alzheimer’s disease for review by the European Medicines Agency. The “timely acceptance” of the MAA for blarcamesine reflects at least in part the EMA’s recognition of the severe unmet medical need in Alzheimer’s, the analyst tells inve

TipRanks last month

AVXL
Anavex Life Sciences Faces Manufacturing Challenges Impacting Product Launch and Financial Stability

Anavex Life Sciences (AVXL) has disclosed a new risk, in the Manufacturing category. Anavex Life Sciences faces potential risks associated with material modifications in the manufacturing methods of its product candidates. As these candidates transition from preclinical studies to commercialization, changes in manufacturing techniques can lead to increased costs, delays, and the necessity for additional studies. Such alterations may cause variations in product performance, impacting clinical tri

TipRanks last month

AVXL
We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. last month

AVXL
Anavex Life Sciences Corp (AVXL) Q4 2024 Earnings Call Highlights: Strong Cash Position and ...

Anavex Life Sciences Corp (AVXL) reports a robust cash runway and significant progress in Alzheimer's research, despite ongoing financial challenges.

GuruFocus.com last month

AVXL
Q4 2024 Anavex Life Sciences Corp Earnings Call

Q4 2024 Anavex Life Sciences Corp Earnings Call

Thomson Reuters StreetEvents last month

AVXL
Anavex Life Sciences: Fiscal Q4 Earnings Snapshot

NEW YORK (AP) — Anavex Life Sciences Corp. AVXL) on Monday reported a loss of $11.6 million in its fiscal fourth quarter. On a per-share basis, the New York-based company said it had a loss of 14 cents.

Associated Press Finance last month

AVXL
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its fourth

GlobeNewswire last month

AVXL
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

Blarcamesine: Potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Submission based on favorable ANAVEX®2-73-AD-004 trial results in patients with early Alzheimer’s disease Once daily oral administration of blarcamesine meaningfully slowed clinical decline in early Alzheimer's disease patients, demonstrating a favorable safety profile with no associated neuroimaging adverse events NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sci

GlobeNewswire last month

AVXL
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

Webcast and Conference Call To be Held Monday, December 23, 2024, 8:30 am ETNEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will

GlobeNewswire last month

AVXL
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference

Topline data from ATTENTION-AD Open-Label-Extension (OLE) 96/144-Week trial J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San Francisco, CA NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, includin

GlobeNewswire last month

AVXL
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of A

GlobeNewswire last month

AVXL

Performance overview

Return	12X1.F	S&P 500
YTD	-23.80%	+2.26%
1-year	+49.10%	+22.65%
3-year	-8.90%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Anavex Life Sciences Corp. (12X1.F)

Jim Cramer on Anavex Life Sciences Corp. (AVXL): ‘It’s A Good Spec’

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

Best Momentum Stocks to Buy for January 21st

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?

All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy

Anavex price target raised to $42 from $40 at H.C. Wainwright

Anavex Life Sciences Faces Manufacturing Challenges Impacting Product Launch and Financial Stability

We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Anavex Life Sciences Corp (AVXL) Q4 2024 Earnings Call Highlights: Strong Cash Position and ...

Q4 2024 Anavex Life Sciences Corp Earnings Call

Anavex Life Sciences: Fiscal Q4 Earnings Snapshot

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

Performance overview